Literature DB >> 15485878

Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.

Wei Liu1, Duorong Xu, Hongmei Yang, Hui Xu, Zhenqi Shi, Xuemei Cao, Sunao Takeshita, Jianzhong Liu, Michael Teale, Xu Feng.   

Abstract

Receptor activator of NF-kappa B ligand (RANKL) and its receptor activator of NF-kappa B (RANK) play pivotal roles in osteoclast differentiation and function. However, the structural determinants of the RANK that mediate osteoclast formation and function have not been definitively identified. To address this issue, we developed a chimeric receptor approach that permits a structure/function study of the RANK cytoplasmic domain in osteoclasts. Using this approach, we examined the role of six RANK putative tumor necrosis factor receptor-associated factor-binding motifs (PTM) (PTM1, ILLMT-REE(286-293); PTM2, PSQPS(349-353); PTM3, PFQEP(369-373); PTM4, VYVSQTSQE(537-545); PTM5, PVQEET(559-564); and PTM6, PVQEQG(604-609)) in osteoclast formation and function. Our data revealed that the RANK cytoplasmic domain possesses three functional motifs (PFQEP(369-373), PVQEET(559-564), and PVQEQG(604-609)) capable of mediating osteoclast formation and function. Moreover, we demonstrated that these motifs play distinct roles in activating intracellular signaling. PFQEP(369-373) initiates NF-kappa B, c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38 signaling pathways and PVQEET(559-564) activates NF-kappa B and p38 pathways in osteoclasts, whereas PVQEQG(604-609) is only capable of activating NF-kappa B pathway. Significantly, the revelation of these functional RANK cytoplasmic motifs has not only laid a foundation for further delineating RANK signaling pathways in osteoclasts, but, more importantly, these RANK motifs themselves represent potential therapeutic targets for bone disorders such as osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485878     DOI: 10.1074/jbc.M404687200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

Review 2.  Role of NF-κB in the skeleton.

Authors:  Deborah Veis Novack
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

Review 3.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

4.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

5.  Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.

Authors:  Joel Jules; Zhenqi Shi; Jianzhong Liu; Duorong Xu; Shunqing Wang; Xu Feng
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

6.  Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Authors:  Yuyu Li; Zhenqi Shi; Joel Jules; Shenyuan Chen; Robert A Kesterson; Dongfeng Zhao; Ping Zhang; Xu Feng
Journal:  J Bone Miner Res       Date:  2019-08-02       Impact factor: 6.741

Review 7.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

8.  Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.

Authors:  Jason W Ashley; Erin M McCoy; Daniel A Clements; Zhenqi Shi; Taosheng Chen; Xu Feng
Journal:  Assay Drug Dev Technol       Date:  2010-11-04       Impact factor: 1.738

9.  C/EBPα and PU.1 exhibit different responses to RANK signaling for osteoclastogenesis.

Authors:  Joel Jules; Yi-Ping Li; Wei Chen
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

10.  c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton.

Authors:  Takashi Izawa; Wei Zou; Jean C Chappel; Jason W Ashley; Xu Feng; Steven L Teitelbaum
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.